Impact of therapy with ethylmethylhydroxypyridine succinate on anthropometric parameters and body composition in overweight patients

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Standard approaches to treating excess body weight, including lifestyle modification (LM), do not always achieve comprehensive treatment goals, that makes it necessary to search for pharmacological agents capable of exerting a beneficial effect on metabolic processes.

The aim: to comparatively evaluate three therapeutic strategies efficacy (combination of therapy with ethylmethylhydroxypyridine succinate (Mexidol FORTE 250) + LM; monotherapy with Mexidol FORTE 250; and LM only) in terms of changes in anthropometric and body composition parameters.

Material and methods. 74 overweight female patients (mean age 33.2 ± 0.82 years), randomized into three groups depending on the used treatment strategy were involved in the study. Anthropometric and bioimpedance measurements were assessed at baseline and after a 3-month follow-up.

Results. Patients receiving Mexidol FORTE 250 (in combination with LM or as monotherapy) demonstrated a statistically significantly greater reduction in body weight and total fat mass comparatively to the control group receiving only LM (p <0.001). Combination therapy demonstrated the greatest effect in reducing visceral fat, significantly outperforming monotherapy (p = 0.0136). Monotherapy with Mexidol FORTE 250 demonstrated a significant advantage in preserving lean muscle mass comparatively to using LM alone (p = 0.0014).

Conclusion. Combination therapy with Mexidol FORTE 250 and LM is an optimal strategy for reducing visceral adiposity. Monotherapy with that drug demonstrates a significant protective effect on muscle tissue. Obtained data prove the need for larger studies to confirm the identified effects.

Full Text

Restricted Access

About the authors

Alena K. Abukova

Kh.M. Berbekov Kabardino-Balkarian State University

Author for correspondence.
Email: almaga1811@yandex.ru
ORCID iD: 0009-0008-0312-3846
SPIN-code: 9780-8299

MD, assistant at the Department of faculty therapy of the Medical academy

Russian Federation, Nalchik

Irina K. Almova

Kh.M. Berbekov Kabardino-Balkarian State University

Email: almovairina@mail.ru
ORCID iD: 0009-0006-7051-2935
SPIN-code: 3161-3495

MD, PhD (Medicine), associate professor of the Department of faculty therapy of the Medical academy

Russian Federation, Nalchik

Murat A. Umetov

Kh.M. Berbekov Kabardino-Balkarian State University; Astra-Sfera Research Medical Institute

Email: umetovma@yandex.ru
ORCID iD: 0009-0009-2519-495X
SPIN-code: 9343-5375

MD, Dr. Sci. (Medicine), professor, head of the Department of faculty therapy of the Medical academy

Russian Federation, Nalchik; Nalchik

Timur M. Bitsuev

Kh.M. Berbekov Kabardino-Balkarian State University

Email: timur_kbsu@mail.ru
ORCID iD: 0009-0009-4666-3356

MD, assistant at the Department of applied mathematics and informatics of the Institute of mathematics and natural sciences

Russian Federation, Nalchik

Tembulat K. Khamizov

City Polyclinic No. 3, Nalchik

Email: t.hamizov@yandex.ru
ORCID iD: 0009-0004-8133-026X

MD, urologist

Russian Federation, Nalchik

Ahmed M. Farah

Kh.M. Berbekov Kabardino-Balkarian State University

Email: mowlidkudar@gmail.com
ORCID iD: 0009-0008-7579-784X

assistant at the Department of faculty therapy of the Medical academy

Russian Federation, Nalchik

Mohammad H.M. Suleiman

Kh.M. Berbekov Kabardino-Balkarian State University

Email: mohammadsrahni@gmail.com
ORCID iD: 0009-0001-9426-9670

6th year student, specialty in general medicine, Medical academy

Russian Federation, Nalchik

References

  1. Дедов И.И., Мельниченко Г.А., Шестакова М.В., Трошина Е.А., Мазурина Н.В., Шестакова Е.А. с соавт. Национальные клинические рекомендации по лечению морбидного ожирения у взрослых. Ожирение и метаболизм. 2018;15(1):53–70. [Dedov II, Melnichenko GA, Shestakova MV, Troshina EA, Mazurina NV, Shestakova EA et al. Russian national clinical recommendations for morbid obesity treatment in adults. 3rd revision (morbid obesity treatment in adults). 2018;15(1):53–70 (In Russ.)]. EDN: OUJNNF. https://doi.org/10.14341/OMET2018153-70
  2. Шляхто Е.В., Недогода С.В., Конради А.О., Баранова Е.И., Фомин В.В., Верткин А.Л., Чумакова Г.А. Концепция новых национальных рекомендаций по лечению ожирения. Российский кардиологический журнал. 2017;21(4):7–13. [Shlyakhto EV, Nedogoda SV, Konradi AO, Baranova EI, Fomin VV, Vertkin AL, Chumakova GA. The concept of novel national clinical guidelines on obesity. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2017;21(4):7–13 (In Russ.)]. EDN: VUYIUB. https://doi.org/10.15829/1560-4071-2017-4-7-13
  3. Pischon T, Boeing H, Hoffmann K, Bergmann M, Schulze MB, Overvad K et al. General and abdominal adiposity and risk of death in Europe. N Engl J Med. 2008;359(20):2105–20. PMID: 19005195. https://doi.org/10.1056/NEJMoa0801891
  4. Танашян М.М., Лагода О.В., Антонова К.В. Цереброваскулярная патология и метаболический синдром. Монография. М.: ООО «АСТ 345». 2019; 376 с. [Tanashyan MM, Lagoda OV, Antonova KV. Cerebrovascular pathology and metabolic syndrome. Monograph. Moscow: AST 345 LLC. 2019; 376 pp. (In Russ.)]. ISBN: 978-5-6041430-2-5. EDN: SBMYLF. https://doi.org/10.33901/978-5-6041430-2-5-2019-1-370
  5. Окороков П.Л., Васюкова О.В., Воронцов А.В. Методы оценки количества и распределения жировой ткани в организме и их клиническое значение. Проблемы эндокринологии. 2014;60(3):53–58. [Okorokov PL, Vasyukova OV, Vorontsov AV. The methods for the characteristic of adipose tissue in the organism and their clinical significance. Problemy endocrinologii = Problems of Endocrinology. 2014;60(3):53–58 (In Russ.)]. EDN: TGRPKR. https://doi.org/10.14341/probl201460353-58
  6. Щепанкевич Л.А., Николаев Ю.А., Долгова Н.А., Чипова Д.Т. Оптимизация липидснижающей терапии у пациентов с ишемическим инсультом и сахарным диабетом 2-го типа. Журнал неврологии и психиатрии им. С.С. Корсакова. 2016;116(2):42–45. [Shchepankevich LA, Nikolaev YuA, Dolgova NA, Chipova DT. Optimization of hypolipidemic therapy in patients with ischemic stroke and diabetes mellitus. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(2):42–45 (In Russ.)]. EDN: VNZZNR. https://doi.org/10.17116/jnevro20161162142-45
  7. Башун Н.З., Тишкевич К.А., Жарнова О.А., Пустюльга С.Н. Методы исследования состава тела человека на современном этапе. Вестник Гродненского государственного университета имени Янки Купалы. Серия 5. Экономика. Социология. Биология. 2019;9(1):119–130. [Bashun NZ, Tishkevich KA, Zharnova OA, Pustiulga SN. Methods of studying the composition of human body at the present stage. Vestnik Grodnenskogo gosudarstvennogo universiteta imeni Yanki Kupaly. Seriya 5. Ekonomika. Sotsiologiya. Biologiya = Bulletin of Yanka Kupala State University of Grodno. Series 5. Economics. Sociology. Biology. 2019;9(1):119–130 (In Russ.)]. EDN: PPQHAV.
  8. Ogawa H, Fujitani K, Tsujinaka T, Imanishi K, Shirakata H, Kantani A et al. InBody 720 as a new method of evaluating visceral obesity. Hepatogastroenterology. 2011;58(105):42–44. PMID: 21510284.
  9. McLester CN, Nickerson BS, Kliszczewicz BM, McLester JR. Reliability and agreement of various InBody body composition analyzers as compared to dual-energy X-ray absorptiometry in healthy men and women. J Clin Densitom. 2020;23(3):443–50. PMID: 30472111. https://doi.org/10.1016/j.jocd.2018.10.008
  10. Neeland IJ, Poirier P, Despres JP. Cardiovascular and metabolic heterogeneity of obesity: Clinical challenges and implications for management. Circulation. 2018;137(13):1391–406. PMID: 29581366. PMCID: PMC5875734. https://doi.org/10.1161/CIRCULATIONAHA.117.029617
  11. Bluher M. Adipose tissue dysfunction in obesity. Exp Clin Endocrinol Diabetes. 2009;117(6):241–50. PMID: 19358089. https://doi.org/10.1055/s-0029-1220641
  12. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010;39(4):412–23. PMID: 20392703. PMCID: PMC2886201. https://doi.org/10.1093/ageing/afq034
  13. Batsis JA, Villareal DT. Sarcopenic obesity in older adults: Aetiology, epidemiology and treatment strategies. Nat Rev Endocrinol. 2018;14(9):513–37. PMID: 30065268. PMCID: PMC6241236. https://doi.org/10.1038/s41574-018-0062-9
  14. Воронина Т.А., Литвинова С.А., Гладышева Н.А., Шулындин А.В. Известные и новые представления о механизме действия и спектре эффектов Мексидола. Журнал неврологии и психиатрии им. С.С. Корсакова. 2025;125(5):22–33. [Voronina TA, Litvinova SA, Gladysheva NA, Shulyndin AV. The known and new ideas about the mechanism of action and the spectrum of effects of Mexidol. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(5):22–33 (In Russ.)]. EDN: ECPVEY. https://doi.org/10.17116/jnevro202512505122
  15. Щулькин А.В. Современные представления об антигипоксическом и антиоксидантном эффектах Мексидола. Журнал неврологии и психиатрии им. С.С. Корсакова. 2018;118(12-2):87–93. [Shchulkin AV. A modern concept of antihypoxic and antioxidant effects of Mexidol. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(12-2):87–93 (In Russ.)]. EDN: PPTGEP. https://doi.org/10.17116/jnevro201811812287
  16. Танашян М.М., Малявин А.Г., Антонова К.В., Максимова М.Ю., Раскуражев А.А., Лагода О.В., Кузнецова П.И. Цереброваскулярная патология в клинической практике. Резолюция Экспертного совета Российского научного медицинского общества терапевтов. Журнал неврологии и психиатрии им. С.С. Корсакова. 2025;125(6):105–111. [Tanashyan MM, Malyavin AG, Antonova KV, Maksimova MYu, Raskurazhev AA, Lagoda OV, Kuznetsova PI. Cerebrovascular disease in clinical practice. Resolution of the Expert Council of the Russian Scientific Medical Society of Therapists. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(6):105–111 (In Russ.)]. EDN: PKGAAT. https://doi.org/10.17116/jnevro20251250611
  17. Танашян М.М., Лагода О.В., Антонова К.В. Хронические цереброваскулярные заболевания на фоне метаболического синдрома: новые подходы к лечению. Журнал неврологии и психиатрии им. С.С. Корсакова. 2012;112(11):21–26. [Tanashyan MM, Lagoda OV, Antonova KV. Chronic cerebrovascular diseases associated with metabolic syndrome: New treatment approaches. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2012;112(11):21–26 (In Russ.)]. EDN: PJNAYD.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Assessment of the effect of combination therapy (Mexidol FORTE 250 + lifestyle modification) on body composition (M ± t) in the studied patients (group 1, n = 25)

Download (215KB)
Indexing metadata
3. Fig. 2. Assessment of the effect of monotherapy with Mexidol FORTE 250 on body composition (M ± t) in the studied patients (group 2, n = 25)

Download (223KB)
Indexing metadata
4. Fig. 3. Assessment of the effect of lifestyle modification alone on body composition (M ± t) in the studied patients (3rd (control) group, n = 24)

Download (220KB)
Indexing metadata

Copyright (c) 2025 Bionika Media